These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32026770)

  • 1. Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers.
    Mahmoud A; Elkhalifa D; Alali F; Al Moustafa AE; Khalil A
    Curr Pharm Des; 2020; 26(14):1622-1633. PubMed ID: 32026770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 3. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
    Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
    Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of novel nitrogen-based chalcone analogs on colorectal cancer cells: Insight into the molecular pathways.
    Hassan AF; Hussein O; Al-Barazenji T; Allouch A; Kamareddine L; Malki A; Moustafa AA; Khalil A
    Heliyon; 2024 Mar; 10(5):e27002. PubMed ID: 38463818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fos-like antigen 2 (FOSL2) promotes metastasis in colon cancer.
    Li S; Fang XD; Wang XY; Fei BY
    Exp Cell Res; 2018 Dec; 373(1-2):57-61. PubMed ID: 30114390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
    Sarkhosh-Inanlou R; Imani M; Sam MR
    Biomed Pharmacother; 2020 Dec; 132():110807. PubMed ID: 33068939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
    Qu H; Yin H; Yan S; Tao M; Xie Y; Chen W
    Oncol Rep; 2016 May; 35(5):2927-35. PubMed ID: 26936485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas.
    Sánchez-Tilló E; Pedrosa L; Vila I; Chen Y; Győrffy B; Sánchez-Moral L; Siles L; Lozano JJ; Esteve-Codina A; Darling DS; Cuatrecasas M; Castells A; Maurel J; Postigo A
    JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37870961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells.
    Suman S; Kurisetty V; Das TP; Vadodkar A; Ramos G; Lakshmanaswamy R; Damodaran C
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E151-60. PubMed ID: 24000138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of miR‑143 modulates KRAS expression in colorectal carcinoma cells.
    Liu H; Liu J; Huo J; Li K; Li K; Guo H; Yang Y
    Oncol Rep; 2019 Dec; 42(6):2759-2767. PubMed ID: 31638218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation.
    Shen CJ; Chan RH; Lin BW; Li NC; Huang YH; Chang WC; Chen BK
    Theranostics; 2023; 13(13):4650-4666. PubMed ID: 37649607
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.